Drugs / Tebotelimab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04653038 | Oct 2020 → Mar 2022 | metastatic melanoma | Zai Lab (Shanghai) Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04178460 | Feb 2020 → Mar 2022 | biliary tract cancer, endometrial carcinoma, gastric cancer, triple-negative breast carcinoma | Zai Lab (Shanghai) Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03219268 | Aug 2017 → Feb 2023 | cervical cancer, cholangiocarcinoma, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm +4 | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04212221 | Apr 2020 → Apr 2022 | hepatocellular carcinoma | Zai Lab (Shanghai) Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04634825 | Mar 2021 → Jul 2022 | head and neck squamous cell carcinoma | MacroGenics | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04129320 | Oct 2019 → Oct 2020 | head and neck squamous cell carcinoma | MacroGenics | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04082364 | Sep 2019 → Jan 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | MacroGenics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-07-08 | MacroGenics | Results MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer macrogenics.com ↗
The decision to discontinue the study was based on an internal review of safety data, which included the occurrence of seven fatalities potentially associated with hemorrhagic events in both arms of the study (of 62 total patients treated). |
| 2021-04-10 | MacroGenics | Results MacroGenics Announces Presentations at the 2021 AACR Annual Meeting macrogenics.com ↗ |
| 2020-12-07 | MacroGenics | Results MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting macrogenics.com ↗
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a dose expansion study of tebotelimab, an investigational, bispecific PD-1 × LAG-3 DART® molecule, in patients with diffuse large B-cell lymphoma (DLBCL). |
| 2020-05-13 | MacroGenics | Results MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting macrogenics.com ↗
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting |
All press releases naming this drug 8 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tebotelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04082364 ↗ |
| Known as | MGD013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178460 ↗ |
| Known as | Mgd013 (pd-1 x lag-3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594578 ↗ |
| Action | Inhibit | “a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3” PMID 37857711 ↗ Oct 20232“Lymphocyte activation gene 3 protein inhibitor” CHEMBL4594578 ↗ “Programmed cell death protein 1 inhibitor” CHEMBL4594578 ↗ |
| Modality | Protein / enzyme biologic | “Tebotelimab, a bispecific PD-1×LAG-3 DART molecule” PMID 37857711 ↗ Oct 2023 |
| Route | Intravenous | “1 mg IV every other week” NCT03219268 ↗ |
| Target | LAG3 | “Lymphocyte activation gene 3 protein inhibitor” CHEMBL4594578 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4594578 ↗ |